Study #2018-0639
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Krina Patel
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-258-1113
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.